AVRO News and Press, AVROBIO Inc. From 11/08/22

Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive Gaucher disease program update planned for Wednesday,...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled “Genomic Medicines – Evolving Regulatory Environmen...

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's ( NASDAQ: AVRO ) gene therapy AVR-RD-02 to treat Gaucher disease (GD). Gaucher disease is a rare lysosomal disorder caused by buildup of certain fatty substances in orga...

AVR-RD-02 has previously received Fast Track status from FDA, orphan drug designation in the U.S. and EU, and ILAP designation from the U.K. MHRA AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of geneti...

First five patients in Phase 1/2 trial show systemic gene therapy effect across multiple tissues evaluated, including eyes, skin, gastrointestinal mucosa and neurocognitive system AVROBIO planning to initiate company-sponsored trial in 2023 AVROBIO, Inc . (Nasdaq...

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to Avrobio's ( NASDAQ: AVRO ) gene therapy AVR-RD-02 to treat Gaucher disease. The Innovation Passport is ...

ILAP intended to accelerate regulatory review process and facilitate patient access in U.K. for seriously debilitating and life-threatening diseases AVR-RD-02 has previously received Fast Track status from U.S. FDA and orphan drug designation in the U.S. and EU AVR...

AVROBIO leading industry in combining use of two safety assays to evaluate genotoxicity risk prior to moving into clinical trials New safety assay uses machine learning algorithms and transcriptional profile data designed to assess the genotoxicity risk of integrating vectors ...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at the 29 th Annual Congress...

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's ( NASDAQ: AVRO ) gene therapy AVR-RD-04 to treat cystinosis. Cystinosis is a rare, multisystem genetic disorder characterized by the excess build up of an amino acid cal...